Augmentation Expectations: Finding the Right Treatment for Partial Response in MDD

For many patients with major depressive disorder (MDD), monotherapy with an antidepressant is not enough. Recognizing when and how to augment treatment is crucial for improving outcomes. This session will focus on identifying inadequate responses to antidepressants and determining when adjunctive therapy is warranted. Attendees will explore the mechanisms of action and latest clinical data on FDA-approved and emerging atypical antipsychotics (AAPs) for adjunctive treatment in MDD. Practical strategies for selecting the most appropriate augmentation option and overcoming barriers to optimal use will also be discussed. Join us for an evidence-based discussion to refine your approach to managing partial response in MDD.

Supported by an independent educational grant from Intra-Cellular Therapies, Inc.